

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2024/194714 A8

(43) International Publication Date
26 September 2024 (26.09.2024)

WIPO | PCT

(51) International Patent Classification:

A61K 38/26 (2006.01) A61K 8/97 (2017.01)
C07K 14/605 (2006.01)

(21) International Application Number:

PCT/IB2024/052151

(22) International Filing Date:

06 March 2024 (06.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202321020795 23 March 2023 (23.03.2023) IN

(71) Applicant: ANYA BIOPHARM INC [—/CN]; 6F., No. 378, Changchun Rd., 10487 Taipei, Taipei (TW).

(72) Inventors; and

(71) Applicants: GSCHLIESSER, Siegfried [AT/CN]; 8F., No.16-6, Fuzhou St, Zhongzheng Dist., 100 Taipei City, Taipei (TW). DESAI, Bhushan [IN/IN]; C-304, Lodha Aqua, Antartica, Mira Road East, Thane (IN).

(72) Inventor: PATIL, Saurabh; C-304, Lodha Aqua, Antartica, Mira Road East, Thane (IN).

(74) Agent: VYAS, Kushal; D403, S.G. Business hub, Near Gota Bridge, S.G Highway, Ahmedabad 380060 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: A HIGH BIOAVAILABILITY PHARMACEUTICAL COMPOSITION OF GLP AGONIST FOR ORAL ADMINISTRATION




Fig - 1

(57) Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a GLP receptor agonist or pharmaceutically acceptable salt or derivatives thereof, one or more medium chain fatty acid based permeation enhancers with aromatic functional group, and one or more medium chain fatty acid based permeation enhancers without aromatic functional group. The pharmaceutical composition may optionally further comprise a basifier.

[Continued on next page]

(48) Date of publication of this corrected version:

02 January 2025 (02.01.2025)

(15) Information about Correction:

see Notice of 02 January 2025 (02.01.2025)